Segall Bryant & Hamill, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Segall Bryant & Hamill, LLC
- $7.1 Billion
- Q3 2025
A detailed history of Segall Bryant & Hamill, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 180,849 shares of CRNX stock, worth $7.77 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
180,849
Previous 176,517
2.45%
Holding current value
$7.77 Million
Previous $5.08 Million
48.38%
% of portfolio
0.11%
Previous 0.07%
Shares
4 transactions
Others Institutions Holding CRNX
# of Institutions
243Shares Held
91.7MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.17MShares$394 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$275 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$268 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$249 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$240 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.31B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...